November 9, 2015
Cosentyx shows no further progression in joint damage in over 80% of PsA
Novartis has announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
November 9, 2015
Investigational baricitinib superior to methotrexate monotherapy in achveing clinical remission
Eli Lilly and Company and Incyte Corporation have announced detailed data from the pivotal phase 3 RA-BEGIN study, which show…
November 6, 2015
AstraZeneca buys ZS Pharma
AstraZeneca has entered into a definitive agreement to acquire Nasdaq-listed ZS Pharma, a biopharmaceutical company based in San Mateo, California.
November 6, 2015
FDA approves Genvoya
FDA has approved Genvoya, a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
November 6, 2015
Sanofi and Lexicon to develop sotagliflozin (for diabetics)
Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
November 5, 2015
Johnson&Johnson confimrs acquiring Novira Therapeutics
Johnson & Johnson has announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.
November 5, 2015
Quantum Pharma’s Colonis launches medical devices for side effects of cancer treatment
Colonis, part of Quantum Pharma’s newly formed Niche Pharmaceuticals division, has launched its in-licensed range of patented medical devices to treat…
November 5, 2015
Sanofi and Hanmi in $3.5B license agreement (developing diabetes treatments)
Sanofi and Hanmi Pharmaceutical Co., Ltd. announced Thursday a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.
November 5, 2015
Redx makes managerial changes
Redx, the drug discovery and development company, has made two senior management appointments.
The company on Thursday said that Nicholas Adams is new as Chief Business Officer and Dr Matilda Bingham has been promoted to Executive Director of Redx Oncology Ltd, the Group’s oncology subsidiary.
November 5, 2015
Verona Pharma completes inhibitor study
Verona Pharma has completed patient enrolment for the Phase IIa dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease (COPD), in which the drug is being administered in addition to standard of care bronchodilators.